Paper Review Records
All Paper Review Records
18 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
293
days
Meta‐Analysis: Enhanced Liver Fibrosis ( ELF ) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
AuthorsMatthew F. W. Gee; Donald B. Chalfin; Edward B. De Vol; H. Roma Levy; Artem T. Boltyenkov; Mario Gutierrez Casale; Arun J. Sanyal
Affiliations1. Siemens Healthcare Diagnostics Inc Tarrytown New York USA; 2. Institute of Medical Science, Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada; 3. Department of Epidemiology and Biostatistics, UCSF School of Medicine University of California San Francisco San Francisco California USA; 4. Division of Gastroenterology, Hepatology and Nutrition, Stravitz‐Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University School of Medicine Richmond Virginia USA
6
days
Letter: Defining the Incremental Predictive Value of HBsAg in Hepatocellular Carcinoma Risk Prediction, Authors' Reply
AuthorsYi‐Fan Guo; Chang Guo; Dong Ji; Xiao‐Xia Niu
Affiliations1. Senior Department of Hepatology Chinese PLA General Hospital Beijing China; 2. Peking University 302 Clinical Medical School Beijing China
98
days
Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?
AuthorsPedro Robson Costa Passos; Valbert Oliveira Costa Filho; Guilherme Grossi Lopes Cançado
Affiliations1. Center of Research and Drug Development (NPDM), Federal University of Ceará Fortaleza Ceará Brazil; 2. Biomedical Research Center (NUBIMED), Federal University of Ceará Fortaleza Ceará Brazil; 3. Hospital das Clínicas Federal University of Minas Gerais Belo Horizonte Minas Gerais Brazil; 4. Hospital da Polícia Militar de Minas Gerais Belo Horizonte Minas Gerais Brazil
11
days
Letter: Defining the Incremental Predictive Value of HBsAg in Hepatocellular Carcinoma Risk Prediction
AuthorsYangwenxuan Han; Xi Chen; Yali Zhang
Affiliations1. First Affiliated Hospital of Heilongjiang University of Chinese Medicine Harbin Heilongjiang China
8
days
Letter on: Pre‐Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial. Authors' Reply
AuthorsRakhi Maiwall; Meenu Bajpai; Samba Siva Rao Pasupuleti; Neha Chauhan; Mohit Prajapati; Manya Prasad; Prashant Agarwal; Rajendra Prasad Mathur; Sherin Thomas; Shiv Kumar Sarin
Affiliations1. Department of Hepatology Institute of Liver and Biliary Sciences New Delhi India; 2. Department of Statistics, Department of Applied Mathematics and Statistics Pachhunga University College, Mizoram University (A Central University) Aizawl India
107
days
Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset
AuthorsMaria Mironova; Krishna Padmanabhan; David Schneider; Jörn M. Schattenberg; Rohit Loomba
Affiliations1. MASLD Research Center, Division of Gastroenterology and Hepatology University of California at San Diego La Jolla California USA; 2. Madrigal Pharmaceuticals, Inc. West Conshohocken Pennsylvania USA; 3. Department of Medicine II Saarland University Medical Center Homburg Germany
312
days
Review Article: Accelerating Coeliac Disease Clinical Trials—Beyond Celiac Meeting With Industry, Academics, Patients and the FDA
AuthorsLisa M. Fahey; Robert Anderson; Edwin Liu; Joseph A. Murray; Marie E. Robert; Jocelyn Anne Silvester; Kate Avery; Nelson Cheinquer; Kristie Grebe; Bhargav Tulabandula; Daniel A. Leffler; Beyond Celiac Coalition
Affiliations1. Children's Hospital of Philadelphia Philadelphia Pennsylvania USA; 2. University of Pennsylvania Philadelphia Pennsylvania USA; 3. International Society for the Study of Celiac Disease Groningen the Netherlands; 4. Mackay Base Hospital Mackay Queensland Australia; 5. Children's Hospital Colorado University of Colorado School of Medicine Aurora Colorado USA; 6. Mayo Clinic College of Medicine and Science Rochester Minnesota USA; 7. Yale University School of Medicine New Haven Connecticut USA; 8. Boston Children's Hospital Boston Massachusetts USA; 9. Harvard Medical School Boston Massachusetts USA; 10. Beyond Celiac Ambler Pennsylvania USA; 11. Takeda Cambridge Massachusetts USA; 12. Anokion Cambridge Massachusetts USA; 13. Navigator Medicines Cambridge Massachusetts USA; 14. Chugai Pharmaceuticals Berkeley Height New Jersey USA
7
days
Letter: Interpretation of Cognitive and Clinical Outcomes in the Randomized Trial of Rifaximin for Covert Hepatic Encephalopathy. Authors' Reply
AuthorsHiroki Inada; Yasuhito Tanaka
Affiliations1. Department of Gastroenterology and Hepatology Faculty of Life Sciences, Kumamoto University Kumamoto Japan
50
days
Clinical Trial: Multi‐Strain Probiotic Improves Bile Acid Profile, Microbiome, and Metabolomic Parameters in Patients With History of Bile Acid Malabsorption—A Randomized, Controlled Trial
AuthorsJohn A. Damianos; Ayah Matar; Paula Carlson; Irene Busciglio; Kara J. Jencks; Stephen Johnson; Ruben A. Mars; Purna C. Kashyap; W. Scott Harmsen; Michael Camilleri
Affiliations1. Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology Mayo Clinic Rochester Minnesota USA; 2. Division of Computational Biology Mayo Clinic Rochester Minnesota USA
2
days
Letter: Personalised FODMAP Modulation in IBS—Towards Less Restrictive Dietary Care. Authors' Reply
AuthorsMaría Fernanda Garcia‐Cedillo; María Fernanda Huerta‐de la Torre; Josealberto Sebastiano Arenas‐Martinez; Enrique Coss‐Adame
Affiliations1. Gastrointestinal Motility Laboratory, Department of Gastroenterology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days